Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6211292 | 0.85 | KMT2A (0.66) | KMT2ATLR2TLR1EPHX2OPRD1 | |
| SCHEMBL732427 | 0.85 | KMT2A (0.68) | KMT2ATLR2TLR1EPHX2MDM2 | |
| SCHEMBL13631378 | 0.83 | KMT2A (0.65) | KMT2ATLR2TLR1EPHX2MDM2 | |
| SCHEMBL29625033 | 0.83 | KMT2A (0.65) | KMT2ATLR2TLR1EPHX2MDM2 | |
| SCHEMBL23509572 | 0.82 | KMT2A (0.52) | KMT2ATLR2TLR1MDM2NPSR1 | |
| SCHEMBL30012213 | 0.82 | KMT2A (0.52) | KMT2ATLR2TLR1MDM2NPSR1 | |
| SCHEMBL20415024 | 0.80 | KMT2A (0.52) | KMT2ATLR2TLR1 | |
| SCHEMBL5557644 | 0.80 | KMT2A (0.60) | KMT2ATLR2TLR1EPHX2MDM2 | |
| SCHEMBL17747004 | 0.80 | KMT2A (0.71) | KMT2ATLR2TLR1EPHX2MDM2 | |
| SCHEMBL6209237 | 0.80 | SIRT2 (0.39) | KMT2ATLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1129084-B1 | THIAZOLE DERIVATIVES AS PPAR GAMMA LIGANDS | GLAXO GROUP LTD (GB) | 2005-03-02 | — | — | EP | disclosed |
| US-6541492-B1 | Prevention or treatment of osteoporosis | SMITHKLINE BEECHAM CORPORATION | 2003-04-01 | — | — | US | disclosed |
| US-20020151569-A1 | PPAR gamma ligands | COLLINS JON LOREN (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1129084-A2 | PPAR GAMMA LIGANDS | GLAXO GROUP LIMITED (GB) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027832-A2 | THIAZOLE DERIVATIVES AS PPAR GAMMA LIGANDS | GLAXO GROUP LIMITED (GB) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151569-A1 | PPAR gamma ligands | PPARG, PPARA, PPARD | KMT2A 2866/4885TLR2 1331/4885TLR1 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.